C4 Therapeutics, Inc. entered into a Research Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins, with an upfront cash payment of $16.0 million and potential milestone payments of approximately $740 million.